Tag: Early Access to Medicines Scheme

Promising Innovative Medicine granted to Bulevirtide for Hep D

by Anna Smith | Mar 6, 2019 | News | 0

MYR Pharma’s Bulevirtide has been awarded a Promising Innovative Medicine as a treatment for hepatitis D infections, indicating that the drug is a strong contender for the UK’s Early Access to Medicinces Scheme (EAMS).

Early access to Tecentriq combination granted through EAMS

by Anna Smith | Jan 2, 2019 | News | 0

UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).